Search details
1.
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
N Engl J Med
; 382(6): 514-524, 2020 02 06.
Article
in English
| MEDLINE | ID: mdl-31826360
2.
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.
N Engl J Med
; 381(4): 307-316, 2019 07 25.
Article
in English
| MEDLINE | ID: mdl-31166679
3.
A therapeutic strategy to target distinct sources of IgE and durably reverse allergy.
Sci Transl Med
; 15(726): eadf9561, 2023 12 13.
Article
in English
| MEDLINE | ID: mdl-38091405
4.
Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib.
JCO Precis Oncol
; 52021.
Article
in English
| MEDLINE | ID: mdl-34504990
5.
Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7).
Ther Adv Med Oncol
; 12: 1758835920943065, 2020.
Article
in English
| MEDLINE | ID: mdl-32782490
6.
Evaluation of Absolute Oral Bioavailability and Bioequivalence of Ribociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, in Healthy Subjects.
Clin Pharmacol Drug Dev
; 9(7): 855-866, 2020 10.
Article
in English
| MEDLINE | ID: mdl-32706937
7.
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study.
Breast
; 54: 148-154, 2020 Dec.
Article
in English
| MEDLINE | ID: mdl-33065342
8.
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
J Clin Oncol
; 36(24): 2465-2472, 2018 08 20.
Article
in English
| MEDLINE | ID: mdl-29860922
Results
1 -
8
de 8
1
Next >
>>